A Phase 2 interventional study of Sarilumab in Ankylosing Spondylitis, sponsored by Sanofi. Terminated at 12 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-21.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Spondylitis, Ankylosing with a site in United States — 10 open to participants now, 13 under way, none of them phase 3. Spondylitis, Ankylosing · United States.
Among the 87 studies in Spondylitis, Ankylosing with a site in United States, this one is the 30th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2010, is one of 18 in phase 2, and was the 17th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →10 of the 87 studies in Spondylitis, Ankylosing with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18+
University of Central Florida · Sites in United States
Ages 18–65
Brain Inflammation Collaborative · Sites in United States
Ages 2+ · Healthy volunteers
AndHealth · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 19 · Phase 3 25 · Phase 4 3
First in 1995; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 223 across the 59 interventional studies, 445 across the 28 observational. Of the 68 that completed or were terminated, 40 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 87 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 2 studies filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
1 of the studies in Spondylitis, Ankylosing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04751396M.D. Anderson Cancer CenterTesting of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors | 2027-02-02 |
Add it to your calendar (.ics) → With an account.
Among the 87 studies in Spondylitis, Ankylosing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objective:
The maximum study duration per participant was to be 267 weeks (approximately 5 years) broken down as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Sarilumab 150 mg subcutaneous (SC) injection every week (or every other week in case of safety issue) for 260 weeks, or until commercially available, or until discontinuation of the project, whichever came first.
Drug: Sarilumab
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: SAR153191, REGN88
Percentage of Participants Experiencing Any Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE) and Treatment Discontinuation
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, regardless of the relationship to the investigational medicinal product (IMP). SAE was any untoward medical occurrence that at any dose resulted in death or was life-threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect or was a medically important event. TEAEs were AEs that developed or worsened or became serious during the TEAE period (time from first dose of IMP up to the end of follow-up period).
Time frame: Baseline up to the end of study (66 weeks)
Percentage of Participants Who Achieved 20% Response in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20)
Treatment response for ASAS20 was defined as: Improvement of ≥ 20% and ≥ 1 unit on a 0 (least) to 10 (worst) numerical rating score (NRS) in at least 3 of the 4 ASAS improvement criteria (ASASIC) domains, and no worsening of ≥ 20% and ≥ 1 unit on 0-10 NRS in the remaining domain. The 4 domains included were participant's global disease activity assessment, total back pain, physical function (Bath Ankylosing Spondylitis Functional Index), and Inflammation (mean of last 2 Bath Ankylosing Spondylitis Disease Activity Index questions on morning stiffness).
Time frame: Baseline up to the end of treatment (60 weeks)
The study was conducted at 56 centers in 12 countries. A total of 224 participants were screened between 01 June 2010 and 03 June 2011.
| Milestone | Sarilumab |
|---|---|
| Started | 223 |
| Completed | 0 |
| Not completed | 223 |
| Withdrew: Adverse event | 17 |
| Withdrew: Lack of efficacy | 27 |
| Withdrew: Sponsor's decision to discontinue study | 172 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 4 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, regardless of the relationship to the investigational medicinal product (IMP). SAE was any untoward medical occurrence that at any dose resulted in death or was life-threatening or required inpatient hospitalization or prolongation of existing hospitalization or resulted in persistent or significant disability/incapacity or was a congenital anomaly/birth defect or was a medically important event. TEAEs were AEs that developed or worsened or became serious during the TEAE period (time from first dose of IMP up to the end of follow-up period).
| Percentage of participants | Sarilumab |
|---|---|
| Any TEAE | 67.3 |
| Any treatment-emergent SAE | 5.4 |
| Any TEAE leading to treatment discontinuation | 8.1 |
Treatment response for ASAS20 was defined as: Improvement of ≥ 20% and ≥ 1 unit on a 0 (least) to 10 (worst) numerical rating score (NRS) in at least 3 of the 4 ASAS improvement criteria (ASASIC) domains, and no worsening of ≥ 20% and ≥ 1 unit on 0-10 NRS in the remaining domain. The 4 domains included were participant's global disease activity assessment, total back pain, physical function (Bath Ankylosing Spondylitis Functional Index), and Inflammation (mean of last 2 Bath Ankylosing Spondylitis Disease Activity Index questions on morning stiffness).
| Percentage of participants | Sarilumab |
|---|---|
| Week 0 (n=218) | 30.3 |
| Week 12 (n=207) | 40.1 |
| Week 24 (n=150) | 46.0 |
| Week 36 (n=93) | 41.9 |
| Week 48 (n=37) | 59.5 |
| Week 60 (n=7) | 57.1 |
Collected over All AEs were collected from signature of the informed consent form up to the final visit (Day 414) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sarilumab | — | 12/223 (5.4%) | 62/223 (27.8%) |
| Event | Sarilumab |
|---|---|
| NephrolithiasisRenal and urinary disorders | 2/223 |
| CellulitisInfections and infestations | 1/223 |
| DiverticulitisInfections and infestations | 1/223 |
| GastroenteritisInfections and infestations | 1/223 |
| LaryngitisInfections and infestations | 1/223 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/223 |
| Thyroid neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/223 |
| Crohn's diseaseGastrointestinal disorders | 1/223 |
| Skin necrosisSkin and subcutaneous tissue disorders | 1/223 |
| Ankylosing spondylitisMusculoskeletal and connective tissue disorders | 1/223 |
| Event | Sarilumab |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 21/223 |
| NasopharyngitisInfections and infestations | 16/223 |
| Injection site reactionGeneral disorders | 14/223 |
| Upper respiratory tract infectionInfections and infestations | 13/223 |
| Aphthous stomatitisGastrointestinal disorders | 12/223 |
All enrolled participants who received at least one dose of the study treatment after signature of the informed consent.
| Age, Continuous(Years) | Sarilumab |
|---|---|
| Mean | 41.6 ± 11.3 |
| Sex: Female, Male(Participants) | Sarilumab |
|---|---|
| Female | 63 |
| Male | 160 |
The record gives a start of Jun 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 5 years 6 months after primary completion. A results delay was requested in Jan 2013.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab